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Vulnerable Plaques: From PROSPECT to Prospects. . .
Aloke V. Finn, MD,* Y. Chandrashekhar, MD,† Jagat Narula, MD, PHD‡s
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fodern cardiology can definitely pride
itself for developing techniques de-
signed to restore blood flow in coro-
nary arteries with tight lesions that
ause myocardial ischemia or in the aftermath of
n acute myocardial infarction (MI). However,
espite the advances in diagnosis and interven-
ion, a substantial number of patients continue to
uffer acute adverse events. This population of at
isk patients, much larger than those presenting with
vert ischemia, are at present a blind spot for cardi-
logists. We do not know which of the patients will
uffer an event nor do we know when one will have
ne. While imaging has allowed us to see pathology
nd risk in fascinating detail, it has, however, not
ept up as well for timely identification of near term
isk or to be able to triage patients with need for
rophylactic intervention. This is one area where
echnology, both for detection or treatment, has re-
ained rather inadequate.
It was with this very intention that the
ROSPECT (A Prospective Natural History of
oronary Atherosclerosis) study was designed;
his study prospectively included nearly 700 pa-
ients presenting with acute coronary syndromes
ACS) who underwent a 3-vessel intravascular ul-
rasound (IVUS) imaging after uneventful 1- or
-vessel percutaneous coronary intervention (PCI)
o characterize both the originally-treated (culprit)
esions or unmanipulated (nonculprit) lesions (NCL)
hat might be associated with subsequent risk for
ajor adverse cardiac events (MACE). From the
roximal part of all 3 major coronary arteries, more
han 3,000 NCL were identified by IVUS with a
laque burden of 40% (1). Patients were prospec-
ively followed with the goal of determining the le-
From the *Emory University School of Medicine, Atlanta, Georgia;
†University of Minnesota, Minneapolis, Minnesota; and the ‡Mount
Sinai Medical Center, New York, New York.ion characteristics predictive of future events. By 3
ears, a new MACE had occurred in 20% of pa-
ients, nearly one-half of them arising from the
CL.
PROSPECT also collected a bounty of other
linically important data, beyond what was avail-
ble at first publication. Some of these data were
onfirmed, for the first time in vivo, what was
nown or suspected from other sources, mainly
ostmortem pathology. Yet other data provided
ew insights into behavior of nonculprit vessel
laque. Because the ability to image and detect vul-
erable plaque has significant implications in clinical
are, PROSPECT deserves an in-depth analysis.
his supplement, being sent with the current is-
ue of iJACC, summarizes much of these addi-
ional insights from the PROSPECT study.
hile the supplement was supported by the Car-
iovascular Research Foundation and publication
f this supplement was made possible with unre-
tricted educational grants from Abbott Vascular
nd Volcano Corporation, the peer review process
or these papers was exactly the same as for regu-
ar iJACC papers and completely independent
rom any input from these entities.
CanWe Identify Vulnerable Plaques by Invasive
Imaging?
Most NCL events arose from originally mild an-
giographic stenosis; a mean angiographic diameter
stenosis of 30% at baseline evolved to 65% at the
time of an event. Almost all MACE presented
with severe progressive or unstable angina amena-
ble to PCI, and not death or MI. Significant in-
dependent predictors of NCL-associated MACE
included plaque burden 70% (hazard ratio [HR]:
5), thin-cap fibroatheroma (TCFA) by IVUS de-
scribed as necrotic core abutting lumen (NCAL)
(HR: 3), and a minimal lumen area 4.0 mm2(HR: 3); presence of 2 of 3 characteristics was asso-
n
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335ciated with a 10% likelihood, and all 3 characteris-
tics with an 18% likelihood of a 3-year MACE rate
as compared to only 0.3% in NCL that lacked these
3 characteristics. In essence, the plaques likely to
cause future coronary events were typically severe,
with a large plaque burden and/or a small minimal
lumen area and IVUS-verified NCAL (2). In fact,
o events arose from coronary segments with 40%
laque area involvement.
Should We Routinely Image to Identify Vulnerable
NCL During PCI?
At the first glance, the results of PROSPECT in-
dicate that the criteria for vulnerable plaque de-
tection were in fact identified and perhaps could
be used to define plaques at risk for future events.
While the combination of 3 characteristic NCL
features conferred an HR of 11, almost 90% of
patients with similar plaques did not have a
MACE during the 3-year follow-up. Thus, even
though these criteria offered the markers for over-
all coronary risk, their accuracy for identifying risk
to the patient from any one particular plaque was
not high enough. The overall hard event rates
(death, MI) attributed to NCL were surprisingly
low; most NCL events consisted of hospitalizations
for progressive or unstable angina. Thus, an equally
important message of PROSPECT pertains to the
remarkable outcomes that can be achieved in coro-
nary disease patients with optimal medical therapy.
And that it is not advisable to intervene for high-
risk lesions even if they can be identified.
This overall low NCL event rate must also be
contrasted with the price of 3-vessel invasive in-
terrogation. In PROSPECT, eleven patients (1.6%)
had complications that were directly attributable to
the 3-vessel imaging procedure. These complications
resulted in 3 nonfatal MI (in 0.4% of patients).
From following the PROSPECT results, it be-
comes important that any invasive imaging proce-
dure must be safe enough to justify its use in pa-
tients whose hard event rate is 1% over 3 years.
As such, these data reinforce that currently there
may be no role for intravascular imaging for the
detection of vulnerable plaque in patients with
symptomatic coronary artery disease. Instead the
focus must be on maximization of medical ther-
apy in symptomatic coronary disease to reduce the
risk of cardiovascular events. However, recent
(unpublished) data from the HORIZONS-AMI(Harmonizing Outcomes With Revascularization
and Stents in Acute Myocardial Infarction) trial
suggest that such plaques in patients with ACS
may not typically regress, in contrast to TCFA in
patients with stable ischemic heart disease (3). If
proved to be true, for proposing a local therapy in
PROSPECT (2 or 3 characteristics carrying)
high-risk lesions it will be necessary to demon-
strate that the MACE rates of the best current
drug-eluting stents are 10% at 3 years, and ran-
domized trials will need to be undertaken.
How Representative are the PROSPECT Criteria of
Vulnerability?
From the view of vulnerable plaque detection,
histopathological studies have provided valuable
insight in proposing the criteria important for lo-
calization of high-risk lesions using imaging mo-
dalities and assessing the potential risk for rup-
ture. These morphological criteria that support
the definition of TCFA or vulnerable plaque re-
sults from a rather simple presumption that the
lesion preceding rupture should bear strong re-
semblance in morphology to rupture itself. A ne-
crotic core characterizes plaque rupture with an
overlying thin-disrupted cap infiltrated by macro-
phages; there are few or no smooth muscle cells
within the cap. The thickness of the fibrous cap
near the rupture site measures 25 m, with
95% of caps measuring 65 m. It is precisely
hose lesions with intact fibrous caps of 65 m
observed at other (often times multiple) sites in
the coronary vasculature, in patients dying of
acute plaque rupture, that are designated vulnera-
ble plaques or TCFA. Obviously important cause-
and-effect data are missing from the current para-
digm because of our inability to accurately detect
vulnerable plaques in humans in vivo and because
of the lack of a representative animal model.
Therefore, a major limitation to the vulnerable
plaque paradigm exists partly because the precise
mechanisms of progression from an asymptomatic
stable to high-risk plaque (TCFA) that lead to rup-
ture and thrombosis are incompletely understood.
Further complicating this paradigm is the observa-
tion that plaque progression beyond 50% cross-sec-
tional area narrowing in a vast majority of cases
occurs through repeated ruptures (and healing),
which occur silently; luminal narrowing in essence
increases with increasing number of healed plaque
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336ruptures. At autopsy, only 10% of cases with
acute rupture had not had a previous rupture site.
Therefore, it is not clear that even if pathologi-
cally inspired vulnerable plaque could be detected
they would lead to clinical events.
This issue notwithstanding, how accurate a tool
is IVUS for detecting the aforementioned vulner-
able plaque criteria? Perhaps the most important
criteria relating to vulnerable plaque detection is
accurate measurement of the fibrous cap itself,
which for vulnerable plaque should be 65 m.
Because the resolution of IVUS is 150 to 200
m, it is incapable of identifying the fibrous cap
thickness component of TCFA. Another problem
with IVUS–virtual histology is its failure to dis-
tinguish “lipid pool” from “necrotic core.” This
separation is critical to calling a lesion “fibroathe-
roma” or TCFA, because necrotic core (not lipid
pool) is a critical feature of the latter and not the
former. In fact, the IVUS–virtual histology classi-
fication of plaque morphology into such terms of
pathological intimal thickening and TCFA may
in fact do the field a disservice because it implies
that this technology has the ability to distinguish
with high accuracy different plaque types.
What Are the PROSPECTS for Vulnerable Plaque
Imaging?
Although PROSPECT has offered unprecedented
details of the plaque characteristics by invasive
imaging technology especially pertaining to the
prognostic outcomes, it is important to speculate
as to where our efforts for future investigation
should be focused. As indicated above, the prog-
nosis for patients with ACS after successful PCI
who are medically compliant and closely followed. Kubo T, Maehara A, Mintz GS, et al.
The dynamic nature of coronary artery
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core–rich plaques frnot justify an invasive imaging procedure of non-
negligible risk. However, hundreds of thousands
of people who have not been diagnosed with cor-
onary disease and are not receiving optimal medi-
cal therapy die, arrest, or develop MI every year.
Therefore, the future investigation must focus on
identifying asymptomatic or minimally symptom-
atic patients with large plaque burden, small lu-
minal area (and TCFA if ever possible) through
noninvasive screening (4,5) so that the advantage
of the intensive medical therapy could be fully
obtained (6,7). Similar to what PROSPECT has
done with invasive imaging, even when a nonin-
vasive imaging strategy is able to define the sub-
jects who are at high risk for near term events,
the final question will be to identify those subjects
who would benefit from noninvasive imaging. It
is expected that the emerging field of biomarker
analysis may be able to refine risk categories and
better define those patients worthy of noninvasive
interrogation for a cost effective screening.
As any excellent investigation, the PROSPECT
study has produced more questions than it has an-
swered. A very important question will be—can we
get PROSPECT level data from noninvasive imag-
ing? Furthermore, what pieces of evidence will sat-
isfy us that noninvasive imaging can identify pa-
tients at high risk of developing MACE? It will also
behoove us to ponder how will therapy be different
then? What level of risk for plaque rupture and risk
reduction would be needed to claim benefit with in-
tense therapeutic intervention should noninvasive
imaging make such a diagnosis possible? These ex-
citing questions should undoubtedly be answered in
the next decade of imaging if we are to impact patientis favorable and a mid term hard event rate does care and outcomes significantly.6
7R E F E R E N C E S
1. Stone GW, Maehara A, Lansky AJ, et al.,
for the PROSPECT Investigators. A
prospective natural-history study of
coronary atherosclerosis. N Engl J Med
2011;364:226–35.
. Stone GW, Maehara A, Mintz GS.
The reality of vulnerable plaque de-
tection. J Am Coll Cardiol Img 2011;
4:902– 4.lesion morphology assessed by serial
virtual histology intravascular ultra-
sound tissue characterization. J Am
Coll Cardiol 2010;55:1590–7.
. Motoyama S, Sarai M, Harigaya H, et
al. Computed tomographic angiogra-
phy characteristics of atherosclerotic
plaques subsequently resulting in acute
coronary syndrome. J Am Coll Cardiol
2009;54:49–57.
. Brugaletta S, Garcia-Garcia HM,
Distance of lipid
om the ostium byNIRS in nonculprit coronary arteries.
J Am Coll Cardiol Img 2012;5:
297–9.
. Motoyama S, Kondo T, Sarai M, et al.
Multislice computed tomographic
characteristics of coronary lesions in
acute coronary syndromes. J Am Coll
Cardiol 2007;50:319–26.
. Braunwald E. Noninvasive detection of
vulnerable coronary plaques: locking
the barn door before the horse is stolen
J Am Coll Cardiol 2009;54:58–9.
